Revelation Cuts Gemini Kidney-Injury Trial Budget to ~$7M From ~$60M
REVB sits 36% above its 52-week low of $3.08.
Summary
Revelation plans a Phase 2a study of Gemini in stage 2 or 3 acute kidney injury starting in early 2027, with topline data expected in late 2027. The study is budgeted at roughly $7M versus roughly $60M under the prior approach, cutting expected development spending by about $53M. That matters because the company held just $9.1M of cash at September 30, 2026 and its 10-Q warned it cannot fund a full year of operations — the cheaper design makes the program more financeable, though the $7M still consumes most of the current cash balance. This is a plan reset, not new clinical data; the stock remains a micro-cap after the 1-for-7 reverse split effective October 20, 2026. Study initiation and how the company funds it are the next hard checkpoints, with topline data not due until late 2027.
At the time of this announcement, REVB was trading at $4.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.9M. The 52-week trading range was $3.08 to $40.60. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.